The founder of Invitro group "INVITRO" Ostrovsky Alexander leaves businesses

The new shareholder companies become Mironchik Roman. The managing director of Peregrine Capital Gabyshev Dimitri estimated cost "INVITRO" at 12–15 billion rubles or 5–6 EBITDA for 2022. "INVITRO" exist since 1995, specializes on laboratory diagnostics and rendering medical services. Unites more than 1,9 thousand medical offices in Russian Federation, Belarus, Kazakhstan, Armenia and Kyrgyzstan. The trade publication Vademecum stated consolidated revenues of group in 2021 in 39,2 billion rub...